Javascript must be enabled to continue!
Robert Noyce and Fairchild Semiconductor, 1957–1968
View through CrossRef
Robert Noyce's career at Fairchild Semiconductor sheds light on several developments that were central to the growth of Silicon Valley and the semiconductor industry: entrepreneurship, technical leadership, and the management of growth in a high-technology company. Noyce served as Fairchild Semiconductors first head of R&D and as its general manager for the six years of the company's most dramatic growth. His technical orientation, personal interest in new technologies, and hands-off management style helped establish a culture at the firm that welcomed innovations in research, process technology, manufacturing, and marketing. As Fairchild Semiconductor grew into a multidivisional mass producer, Noyce's entrepreneurial leadership proved inadequate. Communication breakdowns between divisions, coupled with a series of poor decisions by the parent company, further contributed to the decline of Fairchild Semiconductor.
Title: Robert Noyce and Fairchild Semiconductor, 1957–1968
Description:
Robert Noyce's career at Fairchild Semiconductor sheds light on several developments that were central to the growth of Silicon Valley and the semiconductor industry: entrepreneurship, technical leadership, and the management of growth in a high-technology company.
Noyce served as Fairchild Semiconductors first head of R&D and as its general manager for the six years of the company's most dramatic growth.
His technical orientation, personal interest in new technologies, and hands-off management style helped establish a culture at the firm that welcomed innovations in research, process technology, manufacturing, and marketing.
As Fairchild Semiconductor grew into a multidivisional mass producer, Noyce's entrepreneurial leadership proved inadequate.
Communication breakdowns between divisions, coupled with a series of poor decisions by the parent company, further contributed to the decline of Fairchild Semiconductor.
Related Results
Alternative Entrances: Phillip Noyce and Sydney’s Counterculture
Alternative Entrances: Phillip Noyce and Sydney’s Counterculture
Phillip Noyce is one of Australia’s most prominent film makers—a successful feature film director with both iconic Australian narratives and many a Hollywood blockbuster under his ...
If I Had Possession over Judgment Day: Augmenting Robert Johnson
If I Had Possession over Judgment Day: Augmenting Robert Johnson
augmentvb [ɔːgˈmɛnt]1. to make or become greater in number, amount, strength, etc.; increase2. Music: to increase (a major or perfect interval) by a semitone (Collins English Dicti...
Comparing Robert Noyce Scholars and Non- Robert Noyce Scholars Perceptions of Teaching
Comparing Robert Noyce Scholars and Non- Robert Noyce Scholars Perceptions of Teaching
Staffing high schools with highly qualified math and science teachers continues to be a challenge for school districts across the U.S. (NCTAF, 2010; Ingersoll & Merril, 2010). ...
Constructing Built-In Electric Fields with Semiconductor Junctions and Schottky Junctions Based on Mo–MXene/Mo–Metal Sulfides for Electromagnetic Response
Constructing Built-In Electric Fields with Semiconductor Junctions and Schottky Junctions Based on Mo–MXene/Mo–Metal Sulfides for Electromagnetic Response
AbstractThe exploration of novel multivariate heterostructures has emerged as a pivotal strategy for developing high-performance electromagnetic wave (EMW) absorption materials. Ho...
Smart control of light in edge-emitting lasers
Smart control of light in edge-emitting lasers
The invention of the laser triggered the study of light-matter interactions. In turn, the advent of artificial structured materials on micro- and nanometer scales has become a frui...
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab
Background:
Apolipoprotein B (apoB) provides an integrated measure of atherogenic risk. Whether apoB levels and apoB lowering hold incremental predictive information on...
Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation
Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation
Abstract
The ODYSSEY OUTCOMES trial, comprising over 47 000 patient-years of placebo-controlled observation, demonstrated important reductions in the risk of recurre...
Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer
Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer
This randomized clinical trial explores whether hormone intensification at start of androgen deprivation therapy alters selection of androgen receptor (AR) gene alterations within ...

